Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more
Redhill Biopharma Ltd (RDHL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.568x
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has a cash flow conversion efficiency ratio of 0.568x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.51 Million) by net assets ($-4.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Redhill Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Redhill Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Redhill Biopharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Redhill Biopharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Issta Lines Ltd
TA:ISTA
|
0.034x |
|
Arinsiri Land Public Company Limited
BK:ARIN
|
0.011x |
|
Chai Communication Co.,LTD.
KQ:351870
|
0.147x |
|
Cathay Pacific Airways Limited
BE:CTY
|
N/A |
|
Sin Heng Heavy Machinery Ltd
F:SNVA
|
0.017x |
|
LANCOR HOLDINGS LTD.
NSE:LANCORHOL
|
0.193x |
|
Tsodilo Resources Limited
OTCQB:TSDRF
|
0.071x |
|
Savimex Corp
VN:SAV
|
N/A |
Annual Cash Flow Conversion Efficiency for Redhill Biopharma Ltd (2010–2024)
The table below shows the annual cash flow conversion efficiency of Redhill Biopharma Ltd from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.68 Million | $-9.37 Million | 2.001x | +111.56% |
| 2023-12-31 | $2.07 Million | $-35.82 Million | -17.313x | -2971.10% |
| 2022-12-31 | $-48.40 Million | $-29.18 Million | 0.603x | +108.23% |
| 2021-12-31 | $8.88 Million | $-65.05 Million | -7.329x | -109.17% |
| 2020-12-31 | $13.86 Million | $-48.58 Million | -3.504x | -415.95% |
| 2019-12-31 | $60.00 Million | $-40.75 Million | -0.679x | -0.87% |
| 2018-12-31 | $51.19 Million | $-34.46 Million | -0.673x | +32.23% |
| 2017-12-31 | $45.06 Million | $-44.77 Million | -0.993x | -120.43% |
| 2016-12-31 | $62.70 Million | $-28.26 Million | -0.451x | -51.89% |
| 2015-12-31 | $60.08 Million | $-17.83 Million | -0.297x | +39.31% |
| 2014-12-31 | $25.01 Million | $-12.23 Million | -0.489x | +30.88% |
| 2013-12-31 | $11.93 Million | $-8.44 Million | -0.707x | -97.99% |
| 2012-12-31 | $19.02 Million | $-6.79 Million | -0.357x | -43.09% |
| 2011-12-31 | $18.79 Million | $-4.69 Million | -0.250x | -124.39% |
| 2010-12-31 | $-1.59 Million | $-1.63 Million | 1.024x | -- |